Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

耐受性 安慰剂 精神病 双盲 医学 安慰剂对照研究 内科学 不利影响 精神科 心理学 麻醉 病理 替代医学
作者
Clive Ballard,Carol Banister,Zunera Khan,Jeffrey L. Cummings,George Demos,Bruce Coate,James M. Youakim,Randall Owen,Srdjan Stankovic,Elaine B Tomkinson,Joanne McDermid,Delik Ocal,Ingelin Testad,Mustabshira Qayyum,Polychronis Kemos,Olga Borejko,María Megalogeni,Ella Brookes,Anya Petrava,Miguel Da Silva
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:17 (3): 213-222 被引量:187
标识
DOI:10.1016/s1474-4422(18)30039-5
摘要

Pimavanserin is a selective 5-HT2A receptor inverse agonist and antagonist approved in the USA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. No safe or effective pharmacological treatment is approved for psychosis in patients with Alzheimer's disease. Therefore, we aimed to evaluate the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis.We did a phase 2, randomised, double-blind, placebo-controlled, single-centre (with multiple affiliated nursing home sites across the UK) study. We included participants of either sex who were aged 50 years or older with possible or probable Alzheimer's disease and psychotic symptoms including visual or auditory hallucinations, delusions, or both. Participants were randomly assigned (1:1) to 12 weeks of oral treatment with either pimavanserin (two 17 mg tablets daily) or placebo, with use of permuted block sizes of four and stratified by baseline Mini-Mental State Examination (MMSE) total score (<6 or ≥6) and Neuropsychiatric Inventory-Nursing Home version (NPI-NH) psychosis score (<12 or ≥12). Participants, caregivers, the study sponsor, and study personnel at the clinic site were masked to treatment assignment. The primary endpoint was mean change from baseline to week 6 in the NPI-NH psychosis score for pimavanserin versus placebo in the modified intention-to-treat population. Sustained benefit and safety of pimavanserin were assessed through week 12. This study is registered at ClinicalTrials.gov, number NCT02035553.Between Jan 16, 2014, and Oct 27, 2016, 345 participants across 133 nursing homes were screened, of whom 181 were randomly assigned treatment (n=90 pimavanserin and n=91 placebo). 178 participants were included in the modified intention-to-treat population. Mean total baseline NPI-NH psychosis scores were 9·5 (SD 4·8) for the pimavanserin group and 10·0 (5·6) for the placebo group. Mean change in the NPI-NH psychosis score at week 6 was -3·76 points (SE 0·65) for pimavanserin and -1·93 points (0·63) for placebo (mean difference -1·84 [95% CI -3·64 to -0·04], Cohen's d=-0·32; p=0·045). By week 12, no significant advantage for pimavanserin versus placebo was observed for the overall study population (treatment difference -0·51 [95% CI -2·23 to 1·21]; p=0·561). Common adverse events were falls (21 [23%] of 90 participants in the pimavanserin group vs 21 [23%] of 91 in the placebo group), urinary tract infections (20 [22%] vs 25 [28%]), and agitation (19 [21%] vs 13 [14%]). Eight (9%) participants on pimavanserin and 11 (12%) on placebo discontinued treatment because of adverse events. No detrimental effect was observed on cognition or motor function in either group.Pimavanserin showed efficacy in patients with Alzheimer's disease psychosis at the primary endpoint (week 6) with an acceptable tolerability profile and without negative effect on cognition. Further follow-up to week 12 did not show significant advantage for pimavanserin versus placebo.ACADIA Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
激情的星星完成签到,获得积分10
刚刚
奥利奥完成签到 ,获得积分10
刚刚
刚刚
刚刚
坦率的可仁完成签到,获得积分10
刚刚
勿明发布了新的文献求助10
刚刚
庞mou发布了新的文献求助10
1秒前
朴素冰旋完成签到,获得积分10
1秒前
冯家寅完成签到,获得积分10
1秒前
汉堡包的应助被顺利的莺采纳,获得10
1秒前
2秒前
景哉完成签到,获得积分10
2秒前
过时的香氛完成签到,获得积分10
2秒前
清秀迎彤完成签到,获得积分10
2秒前
3秒前
赶紧毕业完成签到 ,获得积分20
3秒前
cza完成签到,获得积分20
3秒前
周博士完成签到,获得积分10
3秒前
3秒前
3秒前
doou发布了新的文献求助10
4秒前
4秒前
要减肥明雪完成签到,获得积分10
4秒前
Alex发布了新的文献求助200
4秒前
Selbst关注了科研通微信公众号
4秒前
Samuelllee完成签到,获得积分10
4秒前
5秒前
5秒前
FeCl发布了新的文献求助10
5秒前
5秒前
爆肝志友完成签到 ,获得积分10
5秒前
羊翊婕发布了新的文献求助10
5秒前
41完成签到,获得积分10
6秒前
刻苦的晓蕾完成签到,获得积分10
6秒前
ML完成签到,获得积分20
6秒前
笑点低的代容完成签到,获得积分10
6秒前
7秒前
619026854发布了新的文献求助10
7秒前
侯明洋发布了新的文献求助10
7秒前
猪猪半桃完成签到 ,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287